First Patient Treated in Test of OLT38, a Dye to Detect Ovarian Cancer Tissue During Surgery

First Patient Treated in Test of OLT38, a Dye to Detect Ovarian Cancer Tissue During Surgery
A Phase 3 clinical trial testing a special dye that "lights up" ovarian tumor tissue during surgery has treated its first participant, On Target Laboratories announced. The dye, called OTL38, is designed to make removal of cancerous tissue more complete and increase patients' survival. "Treating our first patient in a Phase 3 trial is a major milestone achievement for On Target Laboratories," said Martin Low, CEO of On Target Laboratoriesin a press release. "Our work on this Phase 3 trial in ovarian cancer complements our ongoing work with OTL38 in lung cancer as well as the development of our other targeted dyes. On Target's platform of targeted small molecules goes beyond lung and ovarian cancers and will eventually help surgeons precisely identify nearly all solid tumor cancers and a wide range of other diseases," he said. OTL38 is composed of a near-infrared dye attached to a folic acid-targeting molecule. Folic acid is highly produced by ovarian cancers, making it a suitable molecule for targeting tumor cells. The dye is given intravenousy before surgery and within minutes the tumor tissue lights up. Using a near-infrared camera, surgeons will be better able to detect hard-to-find lesions, small cancer lesions, or affected lymph nodes that would be missed otherwise. This is expected to increase the success of the surgery and subsequently extend patients' lives. The pivotal Phase 3 study (
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *